Cancer Research Technology licenses anticancer peptides to Aura
This article was originally published in Scrip
Executive Summary
Cancer Research Technology (CRT), the commercialisation and development arm of Cancer Research UK, has licensed its cancer-targeting peptides to Aura Biosciences to be used in delivering cancer treatments directly to the tumour.